EDGAR·FLOW

iSpecimen Inc. — Form 8-K

Filed November 5, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 88/100
What the filing says
iSpecimen completed acquisition of two AI products from Foldlab AI Ltd. on November 2, 2026: a Disease-Associated Protein Discovery AI Agent and Disease Trend Prediction/Monitoring AI Model. Total consideration: $750,000 cash at closing, up to $1.25M in two $625K milestone payments, and $2.5M in common stock (2,907,977 shares at VWAP, issued November 5, 2026). Stock subject to 5-year lock-up, no-leak-out, and voting restrictions; Foldlab retains all economic rights during restriction period.
Why this rating

Transformational for $2.4M-cap company: $4.5M deal equals ~188% of market cap, diversifies revenue, enters AI/software market, materially expands addressable market beyond biospecimens.

Tradability signal
NO TRADE

No trade: only ~$67k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$0.79 ▼ 3.05%
at our read · unknown
$0.82
+10 min · unknown
$0.79 ▼ 4.14%
+30 min · unknown
$0.80 ▼ 2.34%
+1 hr · unknown
$0.83 ▲ 0.79%
+4 hrs · unknown
$0.82 ▼ 0.06%

The stock had already moved +3.15% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ ISPC · stock on Yahoo Finance ↗

See more from November 5, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.